News for Dong-A ST Co., Ltd. (170900.KS)

PR NewswireCAMBRIDGE, Mass., March 20, 2025 Top-Line Data From MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in April of 2025Announced Positive Top-L

– Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations – Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations…

MetaVia reports positive DA-1241 trial results for MASH

PR NewswireCAMBRIDGE, Mass., Nov. 18, 2024 New Nasdaq Ticker Symbol will be MTVACAMBRIDGE, Mass., Nov. 18, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, In

The growing demand for alopecia treatments is mainly driven by the rising global prevalence of alopecia, influenced by various factors, as well as...

CHMP Recommends the Approval of Dong-A ST's IMULDOSA, a Biosimilar to Stelara ®

Dong-A ST’s biologics license application (BLA) for Imuldosa, submitted in October 2023, is approved by the U.S. Food and Drug Administration Dong-A ST’s biologics…

NRBO stock touches 52-week low at $2.55 amid market challenges

NeuroBo partners for long-acting obesity treatment

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

NeuroBo Pharmaceuticals, Inc. May 2024 NASDAQ: NRBO ...

SkyQuest projects that the erectile dysfunction market will attain a USD 4.73 billion value by 2030, with a CAGR of 8.5% over the forecast period...

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...